$Dare Bioscience(DARE.US)$Dare Bioscience: Under Terms of Grant Agreement, Daré May Get up to About $49 Mln to Support Nonclinical Development of Dare-Larc1
1
4
举报
Sean Parker :
You have to tell me what you use for news because you always post whatever im about to within minutes of me reading it lol.
Sean Parker :
never heard of it so thank you lol. its really happened at least 5 times. ill have the story copied to my clipboard, click on comments, then see that you've already posted it and it has more detail than mine lol...
$Dare Bioscience(DARE.US)$SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced it will receive a payment of $1 million as the latest installment under a grant agreement to advance the development of Daré's investigational contraceptive DARE-LARC1 through nonclinical proof of principle studies and other IND-enabling work to allow for the submission of an Investigational New Drug (IND) Application with the...
$Dare Bioscience(DARE.US)$Great womans health products! Could be a good place to buy! BUT but, be aware shareholders meeting on june 5! Voting on R/S upto a 1-12! But because of the offering causing the big drop. It may be a place to gamble on the Pre R/S pop? Or if you like a bargin? yes R/S more than likely coming but its not supposed to be more than a 1-12 so yes your share count will be lower but your % of loss or gain stays the same! Or if profit shows before R/S sell a...
$Dare Bioscience(DARE.US)$Daré Bioscience Announces Publication In Contraception Of Efficacy And Safety Findings From A Pre-Pivotal Postcoital Test Study Of Ovaprene: An Investigational Hormone-Free Monthly Intravaginal Contraceptive Benzinga· 11 mins ago Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 women Pivotal Phase 3 contraceptive efficacy clinical study of Ovaprene currently enrolling Ovaprene has the potential to be the first FDA-appro...
$Dare Bioscience(DARE.US)$Daré is continuing to interact with the FDA as the FDA reviews, specifically, the data generated on the proposed endpoints to take forward into Phase 3 development. The FDA has indicated it anticipates providing additional feedback on the Phase 3 design in 2Q-2024. Daré's planned Phase 3 study of Sildenafil Cream, 3.6% would be the first ever Phase 3 pivotal study of a therapeutic candidate for the treatment of arousal disorder in women. Daré...
$Dare Bioscience(DARE.US)$Moomoo 24/7· just Daré Bioscience Announces End-of-Phase 2 Meeting With FDA On Development Of Sildenafil Cream, 3.6%; Co. And FDA Aligned On Key Elements Of Phase 3 Program
$Dare Bioscience(DARE.US)$Daré Bioscience Announces Grant From The Bill & Melinda Gates Foundation Of $750,000 To Fund Activities Related To Bacteria-Based Live Biotherapeutic Product Development Benzinga· 3 mins ago
$Dare Bioscience(DARE.US)$Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-Of-Concept Device That Has Transformative Potential For Women's Health As Well As In Treating A Broad Range Of Diseases Benzinga· 1 min ago
$Dare Bioscience(DARE.US)$Daré Bioscience Secures $12M In Royalty-Backed Investment Structure; Daré Issued To The Investor A 5-Year Warrant To Purchase An Aggregate Of 5M Shares Of Daré's Common Stock At An Exercise Price Of $0.3467 Per Share Benzinga· 1 min ago
Sean Parker : You have to tell me what you use for news because you always post whatever im about to within minutes of me reading it lol.
Trytosaveabit楼主 Sean Parker: Hehehe! I use several! Stocktitan is really good!
Sean Parker : never heard of it so thank you lol. its really happened at least 5 times. ill have the story copied to my clipboard, click on comments, then see that you've already posted it and it has more detail than mine lol...
Trytosaveabit楼主 Sean Parker: You should post it anyways! Im sure you have followers that I don’t! So it would get to your followers as well